We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+9.46%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$11.9B
AUM Growth
+$1.4B
(+13%)
Cap. Flow
+$748M
Cap. Flow
% of AUM
6.3%
Top 10 Holdings %
Top 10 Hldgs %
12.11%
Holding
747
New
202
Increased
220
Reduced
153
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASML
ASML
|
+$134M |
| 2 |
STMicroelectronics
STM
|
+$103M |
| 3 |
Meta Platforms (Facebook)
META
|
+$89.9M |
| 4 |
MetLife
MET
|
+$71.9M |
| 5 |
Gilead Sciences
GILD
|
+$70.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TE Connectivity
TEL
|
+$161M |
| 2 |
Eli Lilly
LLY
|
+$153M |
| 3 |
MRSH
Marsh
MRSH
|
+$123M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$91.8M |
| 5 |
Electronic Arts
EA
|
+$79.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.43% |
| 2 | Technology | 17.4% |
| 3 | Industrials | 8.07% |
| 4 | Energy | 6.4% |
| 5 | Financials | 6.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
B
326
DELISTED
Barnes Group Inc.
B
| $8.52M | 0.07% |
+210,951
| New | +$8.31M |
|
327
Workiva
WK
$3.36B
| $8.45M | 0.07% |
106,791
+88,029
| +469% | +$6.61M |
|
|
AKRO
328
DELISTED
Akero Therapeutics
AKRO
| $8.39M | 0.07% |
292,468
+92,036
| +46% | +$2.4M |
|
329
Core & Main
CNM
$8.71B
| $8.37M | 0.07% |
188,476
-46,683
| -20% | -$2.24M |
|
|
CNTA
330
DELISTED
Centessa Pharmaceuticals
CNTA
| $8.26M | 0.07% |
516,379
+392,918
| +318% | +$4.81M |
|
331
Larimar Therapeutics
LRMR
$426M
| $8.15M | 0.07% |
1,244,551
+1,966
| +0.2% | +$15.8K |
|
332
Absci
ABSI
$1.42B
| $7.99M | 0.07% |
2,090,801
+615,725
| +42% | +$2.45M |
|
333
Pultegroup
PHM
$25.3B
| $7.93M | 0.07% |
+55,219
| New | +$7.02M |
|
|
STKL
334
DELISTED
SunOpta
STKL
| $7.79M | 0.07% |
1,220,735
-1,554,090
| -56% | -$9.11M |
|
335
Spyre Therapeutics
SYRE
$9.2B
| $7.77M | 0.07% |
264,256
+1,640
| +0.6% | +$45.7K |
|
336
Lexeo Therapeutics
LXEO
$349M
| $7.7M | 0.06% |
851,961
+27,887
| +3% | +$333K |
|
337
Nurix Therapeutics
NRIX
$2.61B
| $7.57M | 0.06% |
336,879
+34,992
| +12% | +$793K |
|
338
Rhythm Pharmaceuticals
RYTM
$7.62B
| $7.53M | 0.06% |
143,823
+99,576
| +225% | +$4.77M |
|
|
SLN
339
Silence Therapeutics
SLN
$531M
| $7.4M | 0.06% |
406,903
+316,041
| +348% | +$5.88M |
|
340
Cognex
CGNX
$11.8B
| $7.34M | 0.06% |
+181,255
| New | +$7.72M |
|
341
GoodRx Holdings
GDRX
$1.11B
| $7.29M | 0.06% |
1,050,994
+1,006,339
| +2,254% | +$7.9M |
|
342
Diamondback Energy
FANG
$52.1B
| $7.23M | 0.06% |
+41,909
| New | +$8.07M |
|
343
Delta Air Lines
DAL
$61.3B
| $7.21M | 0.06% |
141,860
+7,579
| +6% | +$330K |
|
|
TMHC
344
DELISTED
Taylor Morrison
TMHC
| $7.12M | 0.06% |
+101,313
| New | +$6.49M |
|
|
BCAX
345
Bicara Therapeutics
BCAX
$1.7B
| $7.08M | 0.06% |
+277,969
| New | +$7.09M |
|
|
KALV
346
DELISTED
KalVista Pharmaceuticals
KALV
| $7.04M | 0.06% |
608,253
+457,791
| +304% | +$5.76M |
|
347
Prestige Consumer Healthcare
PBH
$2.51B
| $6.88M | 0.06% |
95,453
+27,405
| +40% | +$1.94M |
|
348
Dianthus Therapeutics
DNTH
$6.29B
| $6.86M | 0.06% |
250,504
+171
| +0.1% | +$4.76K |
|
349
Cytokinetics
CYTK
$10.7B
| $6.81M | 0.06% |
129,035
-69,146
| -35% | -$3.85M |
|
350
Rapid7
RPD
$726M
| $6.81M | 0.06% |
170,644
+13,919
| +9% | +$523K |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q3 2024 Portfolio in Review
As of Q3 2024, Woodline Partners held 747 positions worth $11.9B, up 13% from $10.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Woodline Partners deployed $748M of net new capital in Q3 2024, opening 202 new positions and adding to 220 existing holdings. Its largest new stake was ASML: 149,876 shares worth $125M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 42% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Eli Lilly, an estimated $153M trimmed.
- Woodline Partners's largest Q3 2024 buy was ASML: 149,876 shares worth $125M.
- Woodline Partners added most to STMicroelectronics in Q3 2024, an estimated $103M increase.
- Woodline Partners's biggest Q3 2024 reduction was Eli Lilly, cutting an estimated $153M.
- Woodline Partners fully exited TE Connectivity in Q3 2024, selling an estimated $161M.
- Woodline Partners's ten largest holdings make up 12% of its $11.9B portfolio in Q3 2024.
- Woodline Partners opened 202 new positions and closed 161 in Q3 2024.
- Woodline Partners's portfolio value rose 13% quarter-over-quarter to $11.9B.
Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.